$OPRX
OptimizeRx Corp Stock $oprx

$oprx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023086885 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q1
Revenue	$28.37M	$16.33M	$13.00M
YoY Change	44.34%	8.26%	-5.31%
Cost Of Revenue	$10.53M	$6.531M	$5.570M
YoY Change	46.22%	15.3%	-1.07%
Gross Profit	$17.84M	$9.800M	$7.433M
YoY Change	43.25%	4.03%	-8.25%
Gross Profit Margin	62.89%	60.01%	57.17%
Selling, General & Admin	$18.86M	$12.89M	$14.03M
YoY Change	-29.3%	238.13%	23.19%
% of Gross Profit	105.7%	131.5%	188.78%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.002M	$470.0K	$463.9K
YoY Change	119.39%	-8.88%	-1.61%
% of Gross Profit	5.61%	4.8%	6.24%
Operating Expenses	$19.86M	$13.35M	$14.50M
YoY Change	49.15%	1.34%	22.2%
Operating Profit	-$2.023M	-$3.553M	-$7.063M
YoY Change	134.08%	-5.41%	87.8%
Interest Expense	-$1.336M	$690.0K	$665.5K
YoY Change	-348.12%	137.96%
% of Operating Profit
Other Income/Expense, Net	$500.0K	$688.2K	$665.5K
YoY Change		137.33%	22182300.0%
Pretax Income	-$11.74M	-$2.865M	-$6.398M
YoY Change	3502.79%	-17.35%	70.1%
Income Tax	-$7.598M
% Of Pretax Income
Net Earnings	-$4.141M	-$2.865M	-$6.398M
YoY Change	1170.99%	-17.35%	70.1%
Net Earnings / Revenue	-14.6%	-17.54%	-49.2%
Basic Earnings Per Share		-$0.17	-$0.37
Diluted Earnings Per Share	-$0.23	-$0.17	-$0.37
COMMON SHARES
Basic Shares Outstanding	18.15M shares	16.64M shares	17.10M shares
Diluted Shares Outstanding		16.64M shares	17.09M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.85M	$63.50M	$73.70M
YoY Change	-81.32%	-19.41%	-17.15%
Cash & Equivalents	$13.85M	$9.921M	$16.44M
Short-Term Investments	$0.00	$53.60M	$57.26M
Other Short-Term Assets	$3.189M	$3.000M	$4.015M
YoY Change	39.84%	10.17%	-12.9%
Inventory
Prepaid Expenses		$3.009M
Receivables	$36.25M	$20.84M	$18.16M
Other Receivables	$1.036M	$0.00	$0.00
Total Short-Term Assets	$54.33M	$87.39M	$95.88M
YoY Change	-44.88%	-12.02%	-14.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$722.3K	$149.3K	$143.9K
YoY Change	425.51%	3.62%	4.72%
Goodwill	$78.36M	$22.67M	$22.67M
YoY Change	245.58%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$568.1K	$1.100M
YoY Change	11148.51%	8453.65%
Total Long-Term Assets	$129.0M	$36.54M	$35.81M
YoY Change	257.71%	0.0%	40.77%
TOTAL ASSETS
Total Short-Term Assets	$54.33M	$87.39M	$95.88M
Total Long-Term Assets	$129.0M	$36.54M	$35.81M
Total Assets	$183.4M	$123.9M	$131.7M
YoY Change	36.18%	-8.79%	-4.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.227M	$700.0K	$1.289M
YoY Change	43.69%	-30.04%	114.55%
Accrued Expenses	$7.976M	$3.109M	$2.125M
YoY Change	206.64%	82.92%	17.67%
Deferred Revenue	$172.0K	$188.0K	$735.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M
YoY Change
Total Short-Term Liabilities	$17.88M	$7.702M	$7.606M
YoY Change	112.98%	25.55%	10.62%
LONG-TERM LIABILITIES
Long-Term Debt	$34.23M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$371.4K	$100.0K	$123.2K
YoY Change	157.0%	-40.03%	-42.13%
Total Long-Term Liabilities	$34.60M	$100.0K	$123.2K
YoY Change			-42.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.88M	$7.702M	$7.606M
Total Long-Term Liabilities	$34.60M	$100.0K	$123.2K
Total Liabilities	$56.82M	$7.822M	$7.729M
YoY Change	565.32%	24.14%	9.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$64.26M	-$60.12M	-$53.09M
YoY Change	37.62%	29.66%
Common Stock	$19.90K	$18.39K	$18.33K
YoY Change	8.8%	0.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.741K	$1.741K	$1.214K
YoY Change	43.41%	146.6%
Treasury Stock Shares
Shareholders Equity	$126.6M	$116.1M	$124.0M
YoY Change
Total Liabilities & Shareholders Equity	$183.4M	$123.9M	$131.7M
YoY Change	36.18%	-8.79%	-4.67%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q1
OPERATING ACTIVITIES
Net Income	-$4.141M	-$2.865M	-$6.398M
YoY Change	1170.99%	-17.35%	70.1%
Depreciation, Depletion And Amortization	$1.002M	$470.0K	$463.9K
YoY Change	119.39%	-8.88%	-1.61%
Cash From Operating Activities	-$6.259M	$1.470M	-$86.33K
YoY Change	-323.26%	-57.54%	-102.12%
INVESTING ACTIVITIES
Capital Expenditures	-$778.6K	$320.0K	$28.58K
YoY Change	-537.23%	-1471.62%	-297.38%
Acquisitions
YoY Change
Other Investing Activities	-$26.78M	-$690.0K	-$1.326M
YoY Change	46.26%	-98.16%	2487.11%
Cash From Investing Activities	-$26.00M	-$1.010M	-$1.549M
YoY Change	40.64%	-97.31%	2255.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	36.19M	-350.0K	-$129.8K
YoY Change	-586.47%	-97.09%	-150.28%
NET CHANGE
Cash From Operating Activities	-6.259M	1.470M	-$86.33K
Cash From Investing Activities	-26.00M	-1.010M	-$1.549M
Cash From Financing Activities	36.19M	-350.0K	-$129.8K
Net Change In Cash	3.934M	110.0K	-$1.765M
YoY Change	-117.01%	-100.24%	-141.31%
FREE CASH FLOW
Cash From Operating Activities	-$6.259M	$1.470M	-$86.33K
Capital Expenditures	-$778.6K	$320.0K	$28.58K
Free Cash Flow	-$5.481M	$1.150M	-$114.9K
YoY Change	-308.75%	-67.01%	-102.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38543
	dei	Entity Registrant Name EntityRegistrantName	OptimizeRx Corporation
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1265381
	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Charles Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
	dei	City Area Code CityAreaCode	248
	dei	Local Phone Number LocalPhoneNumber	651-6568
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	OPRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18152478	shares
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9921475	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	53620576	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	55931821	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20838762	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22155301	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3008858	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2280828	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	87389671	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98576635	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149304	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2023Q3	us-gaap	Goodwill Goodwill	22673820	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2023Q3	oprx	Technology Assets Net TechnologyAssetsNet	7548337	usd
CY2022Q4	oprx	Technology Assets Net TechnologyAssetsNet	7702895	usd
CY2023Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1777669	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1940178	usd
CY2023Q3	us-gaap	Deferred Costs DeferredCosts	300000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	148642	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235320	usd
CY2023Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3141709	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3384889	usd
CY2023Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	800000	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	36390177	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	35937102	usd
CY2023Q3	us-gaap	Assets Assets	123929152	usd
CY2022Q4	us-gaap	Assets Assets	134651185	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	691159	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1549979	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3108908	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2601246	usd
CY2023Q3	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3685390	usd
CY2022Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3990440	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27687	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89902	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	188394	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7701538	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8395876	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	120955	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144532	usd
CY2023Q3	us-gaap	Liabilities Liabilities	7822493	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8540408	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18386920	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18386920	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18288571	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18288571	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	18387	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18289	usd
CY2023Q3	oprx	Treasury Stock Par Value TreasuryStockParValue	0.001
CY2022Q4	oprx	Treasury Stock Par Value TreasuryStockParValue	0.001
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1741397	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1214398	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1741	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1214	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176206572	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172785800	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60116559	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46692098	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	116106659	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123929152	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134651185	usd
CY2023Q3	us-gaap	Revenues Revenues	16331484	usd
CY2022Q3	us-gaap	Revenues Revenues	15085504	usd
	us-gaap	Revenues Revenues	43152560	usd
	us-gaap	Revenues Revenues	42795699	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	6531183	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	5664733	usd
	us-gaap	Cost Of Revenue CostOfRevenue	18093949	usd
	us-gaap	Cost Of Revenue CostOfRevenue	16283307	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	9800301	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	9420771	usd
	us-gaap	Gross Profit GrossProfit	25058611	usd
	us-gaap	Gross Profit GrossProfit	26512392	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12887083	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12661703	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39161752	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36373298	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	466706	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	515828	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1395400	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1565484	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	13353789	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	13177530	usd
	us-gaap	Operating Expenses OperatingExpenses	40557152	usd
	us-gaap	Operating Expenses OperatingExpenses	37938782	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3553488	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3756759	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15498541	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11426390	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	688190	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	289967	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2074081	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	313786	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2865298	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3466792	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13424460	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11112604	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2865298	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466792	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13424460	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11112604	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16637606	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17981184	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16907482	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17994288	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16637606	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17981184	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16907482	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17994288	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1466694	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2913809	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40606	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-170400	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6397714	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123963772	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1654770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1848353	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	105100	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-72961	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7522426	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4161449	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	115815159	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1598315	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1607912	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-49428	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2865298	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	116106659	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	905744	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2268354	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	258128	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3761098	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	131050845	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1336810	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2688513	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	572347	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9374455	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	321054	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3884714	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	140817202	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1381512	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2895729	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	219629	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-34560	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	12240517	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466792	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	129572203	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13424460	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11112604	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1395400	usd
	oprx	Us Healthcare Providers Percentage USHealthcareProvidersPercentage	0.60	pure
	us-gaap	Stock Issued1 StockIssued1	9374455	usd
CY2022Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	5916318	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1565484	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11089853	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11476662	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	478086	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	132727	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-838453	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6854150	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	728030	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2199333	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-858820	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	393817	usd
	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-305049	usd
	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-1704593	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	508548	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1237689	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	24084	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-716693	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-981935	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7850594	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81767	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64667	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	162777510	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	37468889	usd
	oprx	Redemptions Of Heldtomaturity Investments RedemptionsOfHeldtomaturityInvestments	-165088755	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3796	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	158321	usd
	us-gaap	Payments For Software PaymentsForSoftware	1561447	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	664235	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39691877	usd
	oprx	Cash Paid For Employee Withholding Taxes Related To The Vesting Of Restricted Stock Units CashPaidForEmployeeWithholdingTaxesRelatedToTheVestingOfRestrictedStockUnits	-292789	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7522426	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	12561571	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	145706	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1050104	usd
	us-gaap	Origination Of Loans To Employee Stock Ownership Plans OriginationOfLoansToEmployeeStockOwnershipPlans	300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7969509	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11511467	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8287209	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43352750	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84681770	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9921475	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41329020	usd
	oprx	Rou Assets Obtained In Exchange For Lease Obligations ROUAssetsObtainedInExchangeForLeaseObligations	158191	usd
	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid	708334	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	735140	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	1293044	usd
CY2023Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	9619380	usd
CY2022Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	7373802	usd
CY2023Q2	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	9336027	usd
CY2022Q2	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	7122677	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	142662	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	254547	usd
CY2023Q3	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	761447	usd
CY2022Q3	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	0	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	4598280	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3582735	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	188394	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	164309	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	164309	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1389907	usd
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	8778893	usd
CY2022Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	6013181	usd
CY2023Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	9349724	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	451787	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	1041919	usd
CY2023Q3	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	11400132	usd
CY2022Q3	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	9611912	usd
CY2023Q3	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	11136739	usd
CY2022Q3	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	9243207	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	188394	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	673214	usd
CY2023Q3	us-gaap	Revenues Revenues	16331484	usd
CY2022Q3	us-gaap	Revenues Revenues	15085504	usd
	us-gaap	Revenues Revenues	43152560	usd
	us-gaap	Revenues Revenues	42795699	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	5800	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	60520	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	72208	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	26995	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	36552	usd
	us-gaap	Lease Cost LeaseCost	87515	usd
	us-gaap	Lease Cost LeaseCost	108760	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9032	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	36129	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	36129	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	36129	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	36129	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	18065	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	171613	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22971	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	148642	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0632	pure
CY2023Q3	us-gaap	Lease Deposit Liability LeaseDepositLiability	53027	usd
CY2022Q3	us-gaap	Lease Deposit Liability LeaseDepositLiability	66244	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	60095	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	75719	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	60520	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	77011	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	16645523	shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	17074173	shares
CY2023Q3	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	1741397	shares
CY2022Q4	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	1214398	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	10000	shares
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	9668	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	105100	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40606	usd
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	68751	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	43701	shares
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	28006	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	219629	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	572347	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	258128	usd
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	10149	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	35260	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	33272	shares
	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	19488	shares
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	260710	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	5438	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	13627	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	240741	shares
CY2022Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	9374455	usd
CY2023Q1	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	15000000	usd
CY2023Q2	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	15000000	usd
CY2023Q2	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	526999	shares
CY2023Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	7522426	usd
CY2022Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	20000000	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1214398	shares
CY2022	us-gaap	Insurance Commissions InsuranceCommissions	20021830	usd
	oprx	Remaining Expenses RemainingExpenses	10177841	usd
	oprx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P1Y9M
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	12600	usd
	oprx	Restricted Stock Granted Remains Value RestrictedStockGrantedRemainsValue	11247274	usd
	oprx	Remains To Be Recognized Over A Period RemainsToBeRecognizedOverAPeriod	P1Y10M17D
CY2023Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	86685	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	161698	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2500000
CY2021Q4	oprx	Marketbased Restricted Stock Units MarketbasedRestrictedStockUnits	182398	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1900000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2865298	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466792	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13424460	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11112604	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16637606	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17981184	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16907482	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17994288	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16637606	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17981184	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16907482	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17994288	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7433	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63471	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17736	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	99587	shares
CY2023Q3	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	3739	shares
CY2022Q3	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	43751	shares
	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	23341	shares
	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	76010	shares
CY2023Q3	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	11172	shares
CY2022Q3	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	107222	shares
	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	41077	shares
	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	175597	shares
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21500000	usd
CY2023Q4	us-gaap	Business Combination Price Of Acquisition Expected BusinessCombinationPriceOfAcquisitionExpected	95000000	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	554741	usd
	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	589691	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	10500000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1444581	shares
CY2023Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	40000000	usd
CY2023Q4	oprx	Equal Principal Percentage EqualPrincipalPercentage	0.0125	pure
CY2023Q3	us-gaap	Origination Of Loans To Employee Stock Ownership Plans OriginationOfLoansToEmployeeStockOwnershipPlans	300000	usd
	us-gaap	Origination Of Loans To Employee Stock Ownership Plans OriginationOfLoansToEmployeeStockOwnershipPlans	300000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	oprx	Redemptions Of Heldtomaturity Investments RedemptionsOfHeldtomaturityInvestments		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Payments For Software PaymentsForSoftware		usd
	oprx	Cash Paid For Employee Withholding Taxes Related To The Vesting Of Restricted Stock Units CashPaidForEmployeeWithholdingTaxesRelatedToTheVestingOfRestrictedStockUnits		usd
	us-gaap	Origination Of Loans To Employee Stock Ownership Plans OriginationOfLoansToEmployeeStockOwnershipPlans		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	oprx	Rou Assets Obtained In Exchange For Lease Obligations ROUAssetsObtainedInExchangeForLeaseObligations		usd
	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
CY2022Q3	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001448431

Files In Submission

Name	View Source	Status
0001213900-23-086885-index-headers.html	Edgar Link	pending
0001213900-23-086885-index.html	Edgar Link	pending
0001213900-23-086885.txt	Edgar Link	pending
0001213900-23-086885-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_optimizerx.htm	Edgar Link	pending
f10q0923ex31-2_optimizerx.htm	Edgar Link	pending
f10q0923ex32-1_optimizerx.htm	Edgar Link	pending
f10q0923_optimizerx.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oprx-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
oprx-20230930_def.xml	Edgar Link	unprocessable
oprx-20230930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
oprx-20230930_lab.xml	Edgar Link	unprocessable
oprx-20230930_pre.xml	Edgar Link	unprocessable
f10q0923_optimizerx_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPRX
OptimizeRx Corp Stock $oprx

2023 Q4 Form 10-Q Financial Statement

#000121390023086885 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX OptimizeRx Corp Stock $oprx

2023 Q4 Form 10-Q Financial Statement

#000121390023086885 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX
OptimizeRx Corp Stock $oprx